Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMMUNIC, INC. Director's Dealing 2024

Mar 6, 2024

10196_dirs_2024-03-06_16f6f43d-b93b-4249-ad68-b7a7e22b64ca.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IMMUNIC, INC. (IMUX)
CIK: 0001280776
Period of Report: 2024-03-04

Reporting Person: Neermann Joerg (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-03-04 Stock Option $13.63 D 29959 Disposed 2029-07-22 Common Stock (29959) Direct
2024-03-04 Stock Option $12.30 D 15000 Disposed 2030-07-01 Common Stock (15000) Direct
2024-03-04 Stock Option $14.77 D 10000 Disposed 2031-06-10 Common Stock (10000) Direct
2024-03-04 Stock Option $3.40 D 10000 Disposed 2032-06-15 Common Stock (10000) Direct
2024-03-04 Stock Option $1.72 A 64959 Acquired Common Stock (64959) Direct

Footnotes

F1: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.